Abstract
Epicardial adipose tissue (EAT) is a quantifiable and modifiable biomarker. EAT is a marker of visceral adiposity and strongly correlates with fatty liver infiltration and insulin resistance. EAT has shown to correlate and predict the risk of developing the metabolic syndrome, although there is no consensus on the EAT threshold risk values, yet. Higher EAT is associated with higher cardiometabolic risk, independently of traditional risk markers. Imaging of EAT can stratify the cardiovascular risk in subjects with type 2 diabetes and pre-diabetes. EAT increases the risk of cardiovascular diseases in patients with HIV, psoriasis, and postmenopausal women. EAT measurement can serve as a diagnostic tool in assessing cardiovascular and metabolic risk.